Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cited by (1,010)

Items 101–200 of 1,010

1. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
   Stein-Thoeringer, Christoph K., Saini, Neeraj Y., Zamir, Eli, Blumenberg, Viktoria, Schubert, Maria-Luisa, Mor, Uria, Fante, Matthias A., Schmidt, Sabine, Hayase, Eiko, Hayase, Tomo et al. · 2023 · Nature Medicine
2. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
   Zinaida Good, Jay Y. Spiegel, Bita Sahaf, Meena B. Malipatlolla, Zachary J. Ehlinger, Sreevidya Kurra, Moksha H. Desai, Warren D. Reynolds, Anita Wong Lin, Panayiotis Vandris et al. · 2022 · Nature Medicine
3. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
   Naval Guastad Daver, Ahmad S. Alotaibi, Veit Bücklein, Marion S. Subklewe · 2021 · Leukemia
4. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
   Sattva Swarup Neelapu, Caron Alyce Jacobson, Armin Ghobadi, David Bernard Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian Thomas Hill, John M. Timmerman et al. · 2023 · Blood
5. Synthetic cytokine circuits that drive T cells into immune-excluded tumors
   Greg M. Allen, Nicholas W. Frankel, Nishith R. Reddy, Hersh K. Bhargava, Maia A. Yoshida, Sierra R. Stark, Megan C. Purl, Jungmin Lee, Jacqueline L. Yee, Wei Yu et al. · 2022 · Science
6. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
   Chong-xian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li, Lei Zheng · 2020 · Journal of Hematology & Oncology
7. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
   John Kent Lin, Lori S. Muffly, Michael Alexander Spinner, James I. Barnes, Douglas K Owens, Jeremy D. Goldhaber‐Fiebert · 2019 · Journal of Clinical Oncology
8. DLL3: an emerging target in small cell lung cancer
   Dwight Hall Owen, Michael J. Giffin, Julie M. Bailis, Marie-Anne Damiette Smit, David Paul Carbone, Kai He · 2019 · Journal of Hematology & Oncology
9. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
   Matthew J. Frigault, Jörg Dietrich, Maria Martinez‐Lage, Mark B. Leick, Bryan D. Choi, Zachariah Michael DeFilipp, Yi‐Bin Chen, Jeremy S. Abramson, Jennifer Leigh Crombie, Philippe A. Armand et al. · 2019 · Blood
10. Engineered hydrogels for mechanobiology
    Ulrich Blache, Eden M. Ford, Byung Hang Ha, Laura Rijns, Ovijit Chaudhuri, Patricia Y. W. Dankers, April M. Kloxin, Jess Gerrit Snedeker, Eileen Gentleman · 2022 · Nature Reviews Methods Primers
11. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
    Chelsea Camille Pinnix, Jillian Rebecca Gunther, Bouthaina Shbib Dabaja, Paolo Strati, Penny Fang, Misha Hawkins, Sherry Adkins, Jason R. Westin, Sairah Ahmed, Luis Fayad et al. · 2020 · Blood Advances
12. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
    Sebastian P. Haen, Markus W. Loeffler, Hans‐Georg Rammensee, Peter Brossart · 2020 · Nature Reviews Clinical Oncology
13. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
    Martina Pennisi, Miriam Sánchez‐Escamilla, Jessica R. Flynn, Roni Shouval, Ana Alarcón Tomás, Mari Lynne Silverberg, Connie Lee Batlevi, Renier J. Brentjens, Parastoo Bahrami Dahi, Sean M. Devlin et al. · 2021 · Blood Advances
14. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
    Julio C. Chávez, Christina A. Bachmeier, Mohamed A. Kharfan‐Dabaja · 2019 · Therapeutic Advances in Hematology
15. The journey of CAR-T therapy in hematological malignancies
    Junru Lu, Guan Jiang · 2022 · Molecular Cancer
16. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
    Morgane Boulch, Marine Cazaux, Yann Loe-Mie, Ronan Thibaut, Béatrice Corre, Fabrice Lemaı̂tre, Capucine L. Grandjean, Zacarias Garcia, Philippe Bousso · 2021 · Science Immunology
17. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
    Louai Labanieh, Robbie G. Majzner, Dorota Danuta Klysz, Elena Sotillo, Chris Fisher, José G. Vilches-Moure, Kaithlen Zen Pacheco, Meena B. Malipatlolla, Peng Xu, Jessica H. Hui et al. · 2022 · Cell
18. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
    Paolo Strati, Sairah Ahmed, Fateeha Furqan, Luis Fayad, Hun Ju Lee, Swaminathan P. Iyer, Ranjit K. Nair, Loretta J. Nastoupil, Simrit Parmar, Maria Alma Rodriguez et al. · 2021 · Blood
19. Killers 2.0: NK cell therapies at the forefront of cancer control
    Jonathan J. Hodgins, S. Khan, Maria M. Park, Rebecca C. Auer, Michele Ardolino · 2019 · Journal of Clinical Investigation
20. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
    Ranjan Upadhyay, Jonathan Boiarsky, Gvantsa Pantsulaia, Judit Svensson‐Arvelund, Matthew Junda Lin, Aleksandra Wroblewska, Sherry Bhalla, Nathalie Scholler, Adrian I Bot, John M. Rossi et al. · 2021 · Cancer Discovery
21. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
    Wolfgang Andreas Bethge, Peter Martus, Michael W. Schmitt, Udo Holtick, Marion Subklewe, Bastian von Tresckow, Francis Ayuketang Ayuk, Eva Wagner-Drouet, Gerald Georg Wulf, Reinhard Marks et al. · 2022 · Blood
22. CAR T cells for brain tumors: Lessons learned and road ahead
    David Akhavan, Darya Alizadeh, Dongrui Wang, Michael R. Weist, Jennifer Kelly Shepphird, Christine E. Brown · 2019 · Immunological Reviews
23. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees
    Iris M. Otani, Heather K. Lehman, Artemio M. Jongco, Lulu R. Tsao, Antoine Azar, Teresa K. Tarrant, Elissa R. Engel, Jolan Eszter Walter, Tho Q. Truong, David A. Khan et al. · 2022 · Journal of Allergy and Clinical Immunology
24. Current Perspectives in Cancer Immunotherapy
    Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, Massimo Libra, Apostolos Zaravinos · 2019 · Cancers
25. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
    Mark P. Hamilton, Takeshi Sugio, Troy Noordenbos, Shuyu Shi, Philip L. Bulterys, Chih Long Liu, Xiaoman Kang, Mari N. Olsen, Zinaida Good, Saurabh Dahiya et al. · 2024 · New England Journal of Medicine
26. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
    Freyer, Craig W., Porter, David L. · 2020 · Journal of Allergy and Clinical Immunology
27. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
    Gunjan Dagar, Ashna Gupta, Tariq Masoodi, Sabah Nisar, Maysaloun Merhi, Sheema Hashem, Ravi Chauhan, Manisha Dagar, Sameer Mirza, Puneet Bagga et al. · 2023 · Journal of Translational Medicine
28. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
    Stephan Kadauke, Regina M. Myers, Yimei Li, Richard Aplenc, Diane Baniewicz, David Maxwell Barrett, Allison Barz Leahy, Colleen A. Callahan, J. Gregory Dolan, Julie C. Fitzgerald et al. · 2021 · Journal of Clinical Oncology
29. CAR-T Cell Therapy: the Efficacy and Toxicity Balance
    Karan L. Chohan, Elizabeth L. Siegler, Saad S. Kenderian · 2023 · Current Hematologic Malignancy Reports
30. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
    Kedar Kirtane, Hany Elmariah, Christine H. Chung, Daniel Abate‐Daga · 2021 · Journal for ImmunoTherapy of Cancer
31. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
    Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, Olaf Penack, Veit Bücklein, Liv Jentzsch, Dimitrios Mougiakakos, Grace Johnson, Brian Arciola, Cecilia del Carmen Carpio et al. · 2022 · Journal for ImmunoTherapy of Cancer
32. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
    Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan, Xingxing Zang · 2019 · Journal of Hematology & Oncology
33. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
    Ahmed Abbasi, Stephen Zachary Peeke, Nishi Nilesh Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro et al. · 2020 · Journal of Hematology & Oncology
34. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy
    Lupeng Ye, Jonathan Joon-Young Park, Lei Peng, Quanjun Yang, Ryan Dz-Wei Chow, Matthew B. Dong, Stanley Z. Lam, Jianjian Guo, Erting Tang, Yueqi Zhang et al. · 2022 · Cell Metabolism
35. Gene editing for immune cell therapies
    Stefanie R. Bailey, Marcela Valderrama Maus · 2019 · Nature Biotechnology
36. Efficacy and safety of CD19 ‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET , ZUMA ‐1, and TRANSCEND trials
    Jason R. Westin, Marie José Kersten, Gilles Andre Salles, Jeremy S. Abramson, Stephen J. Schuster, Frederick Lundry Locke, Charalambos Babis Andreadis · 2021 · American Journal of Hematology
37. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
    Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita Dwivedy Nasta, Daniel Jeffrey Landsburg, Simon Francis Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. Schuster · 2021 · Blood
38. Advances in Universal CAR-T Cell Therapy
    Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu · 2021 · Frontiers in Immunology
39. Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
    Chiara Francesca Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, Sara Napolitano, Giada Matera, Benedetta Cabiati, Chiara Buracchi, Gianmaria Borleri et al. · 2020 · Journal of Clinical Investigation
40. T cell circuits that sense antigen density with an ultrasensitive threshold
    Rogelio Antonio Hernández-López, Wei Yu, Katelyn A. Cabral, Olivia A. Creasey, Maria del Pilar Lopez Pazmino, Yurie Tonai, Arsenia De Guzman, Anna R. Mäkelä, Kalle Saksela, Zev J. Gartner et al. · 2021 · Science
41. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
    José Saura‐Esteller, Milon de Jong, Lisa A. King, Erik Ensing, Benjamin Winograd, Tanja D. de Gruijl, Paul W.H.I. Parren, Hans J. van der Vliet · 2022 · Frontiers in Immunology
42. HLA-independent T cell receptors for targeting tumors with low antigen density
    Mansilla-Soto, Jorge, Eyquem, Justin, Haubner, Sascha, Hamieh, Mohamad, Feucht, Judith, Paillon, Noémie, Zucchetti, Andrés Ernesto, Li, Zhuoning, Sjöstrand, Maria, Lindenbergh, Pieter L. et al. · 2022 · Nature Medicine
43. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
    Bradley D. Hunter, Caron Alyce Jacobson · 2019 · JNCI Journal of the National Cancer Institute
44. Precision medicine for human cancers with Notch signaling dysregulation (Review)
    Masuko Katoh, Masaru Katoh · 2019 · International Journal of Molecular Medicine
45. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
    Tania Jain, Merav Bar, Ankit J. Kansagra, Elise A. Chong, Shahrukh Khurshid Hashmi, Sattva Swarup Neelapu, Michael Thomas Byrne, Elad Jacoby, Aleksandr Lazaryan, Caron Alyce Jacobson et al. · 2019 · Transplantation and Cellular Therapy
46. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
    Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Alexander Lunning, Michael L. Wang, Jon E. Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Babis Andreadis, Alison R. Sehgal et al. · 2023 · Blood
47. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
    Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G Medhin, Gashaw Dessie Terefe, Fitalew Tadele Admasu, Wondwossen Wale Tesega, Endeshaw Chekol Abebe · 2022 · Human Vaccines & Immunotherapeutics
48. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells
    Sangwook Oh, Xuming Mao, Silvio Manfredo Vieira, Jinmin Lee, Darshil R. Patel, Eun Jung Choi, Andrea Alvarado, Ebony Cottman‐Thomas, Damián Maseda, Patricia Tsao et al. · 2023 · Nature Biotechnology
49. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
    Sònia Guedan, Aviv Madar, Victoria Casado‐Medrano, Carolyn E. Shaw, Anna Wing, Fang Liu, Regina M. Young, Carl H. June, Avery D. Posey · 2020 · Journal of Clinical Investigation
50. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
    Gauthier, Jordan, Bezerra, Evandro D., Hirayama, Alexandre V., Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K., Kimble, Erik L., Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha et al. · 2021 · Blood
51. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
    for the European Society for Blood and Marrow Transplantation (EBMT), Jakob Robert Passweg, Helen Baldomero, Christian Chabannon, Grzegorz Władysław Basak, Selim Corbacioglu, Rafael F. Duarte, Harry Dolstra, Arjan C. Lankester, Mohamad Mohty et al. · 2020 · Bone Marrow Transplantation
52. From concept to cure: The evolution of CAR-T cell therapy
    Kisha K. Patel, Mito Tariveranmoshabad, Siddhant Kadu, Nour Shobaki, Carl H. June · 2025 · Molecular Therapy
53. CAR T‐cell therapy: Full speed ahead
    David J. Sermer, Renier J. Brentjens · 2019 · Hematological Oncology
54. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
    Andrew David Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo Fabrizio Caimi, Julie E Chang, Julio C. Chávez, Beth A. Christian, Luis Fayad et al. · 2019 · Journal of the National Comprehensive Cancer Network
55. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
    Benno Lickefett, Lulu Chu, Valentín Ortiz‐Maldonado, Linda Warmuth, Pere Barba, Matteo Doglio, David Andrew Henderson, Michael Hudecek, Andreas Kremer, Janet L. Markman et al. · 2023 · Frontiers in Immunology
56. Cytokine Release Syndrome: Current Perspectives
    Hemant S. Murthy, Madiha Iqbal, Julio C. Chávez, Mohamed A. Kharfan‐Dabaja · 2019 · ImmunoTargets and Therapy
57. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
    Marco Ruella, Felix Korell, Patrizia Porazzi, Marcela Valderrama Maus · 2023 · Nature Reviews Drug Discovery
58. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
    Mehdi Hamadani, John A. Radford, Carmelo Carlo‐Stella, Paolo Fabrizio Caimi, Erin Gourley Reid, Owen A. O’Connor, Jay Marshall Feingold, Kirit M. Ardeshna, William M. Townsend, Melhem Solh et al. · 2020 · Blood
59. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
    Julia Ruark, Erin Mullane, Nancy Cleary, Ana Cordeiro, Evandro D. Bezerra, Vicky Wu, Jenna M. Voutsinas, Bronwen E. Shaw, Kathryn E. Flynn, Stephanie Joi Lee et al. · 2019 · Transplantation and Cellular Therapy
60. CAR T-cell therapy in hematologic malignancies: a voyage in progress.
    Holstein, Sarah A., Lunning, Matthew A. · 2020 · Clinical Pharmacology & Therapeutics
61. CAR T Cell Toxicity: Current Management and Future Directions
    Lucrecia Yáñez, Miriam Sánchez‐Escamilla, Miguel‐Angel Perales · 2019 · HemaSphere
62. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
    Nirav Niranjan Shah, Theresa Camille Maatman, Parameswaran Hari, Bryon D. Johnson · 2019 · Frontiers in Oncology
63. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells
    Xingying Zhang, Chenze Zhang, Miaomiao Qiao, Chen Cheng, Na Tang, Shan Lu, Wen Ce Sun, Beilei Xu, Yuanwei Cao, Xiaofei Wei et al. · 2022 · Cancer Cell
64. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
    Alexandre V. Vinaud Hirayama, Jordan Gauthier, Kevin Anthony Hay, Jenna M. Voutsinas, Qian Vicky Wu, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Stanley R. Riddell et al. · 2019 · Blood
65. Cardiovascular Effects of CAR T Cell Therapy
    Bénédicte Lefebvre, Yu Kang, Amanda M. Smith, Noelle V. Frey, Joseph R. Carver, Marielle Scherrer‐Crosbie · 2020 · JACC CardioOncology
66. New agents and regimens for diffuse large B cell lymphoma
    Liang Wang, Linrong Li, Ken H. Young · 2020 · Journal of Hematology & Oncology
67. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
    Bai, Zhiliang, Woodhouse, Steven, Zhao, Ziran, Arya, Rahul, Govek, Kiya, Kim, Dongjoo, Lundh, Stefan, Baysoy, Alev, Sun, Hongxing, Deng, Yanxiang et al. · 2022 · Science Advances
68. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
    Martin Wermke, Sabrina Kraus, Armin Ehninger, Ralf Christian Bargou, Maria-Elisabeth Goebeler, Jan Moritz Middeke, Carla Kreissig, Malte v. Bonin, Jan Koedam, Michael Pehl et al. · 2021 · Blood
69. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
    Jason R. Westin, Laurie Helen Sehn · 2022 · Blood
70. The immune landscape and response to immune checkpoint blockade therapy in lymphoma
    Justin Paul Kline, James K. Godfrey, Stephen Maxted Ansell · 2019 · Blood
71. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
    Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, Guillaume Cartron, David Beauvais, Fabien Le Bras, François‐Xavier Gros, Sylvain Choquet, Pierre Bories, Pierre Feugier et al. · 2022 · Blood
72. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
    Austin J. Sim, Michael David Jain, Nicholas B. Figura, Julio C. Chávez, Bijal Dinesh Shah, Farhad Khimani, Aleksandr Lazaryan, Gabriel S. Krivenko, Marco L. Davila, Hien D. Liu et al. · 2019 · International Journal of Radiation Oncology*Biology*Physics
73. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris
    Jinmin Lee, Daniel K. Lundgren, Xuming Mao, Silvio Manfredo Vieira, Selene Nuñez-Cruz, Erik F. Williams, Charles‐Antoine Assenmacher, Enrico Radaelli, Sangwook Oh, Baomei Wang et al. · 2020 · Journal of Clinical Investigation
74. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
    Lu Tang, Zhongpei Huang, Heng Mei, Yu Hu · 2023 · Signal Transduction and Targeted Therapy
75. CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy
    Joshua Aiden Hill, Sergio Giralt, Troy R. Torgerson, Hillard Michael Lazarus · 2019 · Blood Reviews
76. Genetic engineering of T cells for immunotherapy
    Gavin I. Ellis, Neil C. Sheppard, James L. Riley · 2021 · Nature Reviews Genetics
77. Harnessing Features of Adaptive NK Cells to Generate iPSC-Derived NK Cells for Enhanced Immunotherapy
    Karrune V. Woan, Hansol Kim, R. Bjordahl, Z. Davis, S. Gaidarova, J. Goulding, Brian Hancock, S. Mahmood, Ramzey Abujarour, Hong-Bo Wang et al. · 2021 · Cell Stem Cell
78. Treatment strategies for patients with diffuse large B-cell lymphoma
    Stefano Poletto, Mattia Novo, Luca Paruzzo, Pio Manlio Mirko Frascione, Umberto Vitolo · 2022 · Cancer Treatment Reviews
79. The Past, Present, and Future of Non-Viral CAR T Cells
    Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara Francesca Magnani · 2022 · Frontiers in Immunology
80. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
    Martina Pennisi, Tania Jain, Bianca Santomasso, Elena Mead, Kitsada Wudhikarn, Mari Lynne Silverberg, Yakup Batlevi, Roni Shouval, Sean M. Devlin, Connie Lee Batlevi et al. · 2020 · Blood Advances
81. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
    Christopher Austin Klebanoff, Smita S. Chandran, Brian M. Baker, Sergio A. Quezada, Antoni Ribas · 2023 · Nature Reviews Drug Discovery
82. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials
    Tyagarajan, Seshu, Spencer, Tom, Smith, Jonathan · 2020 · Molecular Therapy - Methods & Clinical Development
83. Current challenges and emerging opportunities of CAR-T cell therapies
    Teresa R. Abreu, Nuno André Fonseca, Nélio Gonçalves, João Nuno Moreira · 2019 · Journal of Controlled Release
84. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
    Adam Goldman, Elad Maor, David Bomze, Jennifer E. Liu, Joerg Herrmann, Joshua Alexander Fein, Richard M. Steingart, Syed Mahmood, Wendy L. Schaffer, Miguel‐Angel Perales et al. · 2021 · Journal of the American College of Cardiology
85. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
    Claire Roddie, Lorna Neill, Wendy Osborne, Sunil Iyengar, Eleni Tholouli, David A. Irvine, Sridhar Chaganti, Caroline Besley, Adrian John Clifton Bloor, Ceri H. Jones et al. · 2023 · Blood Advances
86. Emerging immunotherapies in multiple myeloma
    Urvi Ashok Shah, Sham Mailankody · 2020 · BMJ
87. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
    Andrew David Zelenetz, Leo I. Gordon, Julie E Chang, Beth A. Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Lihua Elizabeth Budde, Paolo Fabrizio Caimi, Sven de Vos et al. · 2021 · Journal of the National Comprehensive Cancer Network
88. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
    Roni Shouval, Ana Alarcon Tomas, Joshua Alexander Fein, Jessica R. Flynn, Ettai Markovits, Shimrit Mayer, Aishat Olaide Afuye, Anna Alperovich, Theodora Anagnostou, Michal Judith Besser et al. · 2021 · Journal of Clinical Oncology
89. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
    Matthew R. Bell, Stephen M Gottschalk · 2021 · Frontiers in Immunology
90. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia
    Qian Zhang, Morgan E. Hresko, Lora K. Picton, Leon Su, Michael J. Hollander, Selene Nuñez-Cruz, Zheng Zhang, Charles‐Antoine Assenmacher, Jonathan T. Sockolosky, K. Christopher García et al. · 2021 · Science Translational Medicine
91. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
    Cheng, Jiali, Zhao, Lei, Zhang, Yuanyuan, Qin, Yun, Guan, Yuqi, Zhang, Tong, Liu, Chaohong, Zhou, Jianfeng · 2019 · Frontiers in Oncology
92. Next generations of CAR-T cells - new therapeutic opportunities in hematology?
    Jaromir Tomasik, Marcin Jasiński, Grzegorz Władysław Basak · 2022 · Frontiers in Immunology
93. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
    Mattia D’Agostino, Noopur S Raje · 2019 · Leukemia
94. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial
    Matthew J. Frigault, Jörg Dietrich, Kathleen Gallagher, Mark J. Roschewski, Justin T. Jordan, Deborah Anne Forst, Scott Randall Plotkin, Daniella Cook, Keagan S. Casey, Kevin Lindell et al. · 2022 · Blood
95. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
    Peter Brændstrup, Bruce L. Levine, Marco Ruella · 2020 · Cytotherapy
96. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
    Rakesh Awasthi, Lida Bubuteishvili Pacaud, Edward K Waldron, Constantine Si Lun Tam, Ulrich Jaeger, Peter Borchmann, Samantha Mary Jaglowski, Stephen Ronan Foley, Koen van Besien, Nina D. Wagner‐Johnston et al. · 2020 · Blood Advances
97. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
    Krishna R. Juluri, Qian Vicky Wu, Jenna M. Voutsinas, Jue Hou, Alexandre V. Vinaud Hirayama, Erin Mullane, Nancy Miles, David G. Maloney, Cameron John Turtle, Merav Bar et al. · 2021 · Blood Advances
98. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
    Shakira Jeanene Grant, Alyssa Ann Grimshaw, Juliet Silberstein, Donna L. Murdaugh, Tanya Marya Wildes, Ashley Elizabeth Rosko, Smith Giri · 2022 · Transplantation and Cellular Therapy
99. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
    P. Strati, A. Varma, S. Adkins, L. Nastoupil, J. Westin, F. Hagemeister, N. Fowler, Hun J. Lee, L. Fayad, F. Samaniego et al. · 2020 · Haematologica
100. Exhaustion of CAR T cells: potential causes and solutions
     Taku Kouro, Hidetomo Himuro, Tetsuro Sasada · 2022 · Journal of Translational Medicine